MNKD

Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.

Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years.

MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript

MannKind NASDAQ: MNKD reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased spending tied to product launches and development programs.

MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript

We also report on an experimental diagnostic approach that can ​detect tuberculosis exposure and infection at an earlier stage than current methods.

MNKD Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety & Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that the Company will report second quarter 2026 financial results after market close on Wednesday, August 5, 2026.